Bambuterol is indicated for the management of:

• Bronchial asthma
• Chronic bronchitis
• Emphysema
• Other pulmonary conditions where bronchospasm contributes to breathing difficulty

Bambuterol is a long-acting β2-adrenergic receptor agonist and a prodrug that is converted into terbutaline in the body. It works by selectively stimulating β2 receptors, leading to relaxation of bronchial smooth muscles. Additionally, it helps reduce the release of bronchospasm-inducing substances, decreases airway edema caused by inflammatory mediators, and enhances mucociliary clearance, thereby improving airflow and breathing.

Children 2-5 years: The recommended normal dose 10 mg (10 ml syrup).

Children 6-12 years: The recommended normal dose 10 mg (10 ml syrup). The dose may be increased to 20 mg.

Adult: The recommended initial dose 10 mg. The dose may be increased to 20 mg after 1-2 weeks depending on the clinical effect.

Bambuterol may interact with several medications including succinylcholine, monoamine oxidase inhibitors (MAOIs), β2-blockers, corticosteroids, diuretics, muscle relaxants, and sympathomimetic xanthine derivatives, potentially altering its effects or increasing side effects.

Bambuterol is contraindicated in patients with significant hepatic impairment, including liver cirrhosis or severely reduced liver function.

Common adverse effects include fatigue, nausea, palpitations, headache, dizziness, and tremor.

Although no teratogenic effects have been observed in animal studies, caution is advised during the first trimester of pregnancy. It is unknown whether bambuterol or its metabolites are excreted in human breast milk; therefore, caution is recommended when administered to breastfeeding mothers. Terbutaline, the active metabolite, is known to pass into breast milk, although effects on the infant are unlikely at therapeutic doses. Transient hypoglycemia has been reported in preterm newborns following maternal β2-agonist use.

Dose adjustment may be required in patients with severe renal impairment, genetic deficiency of plasma cholinesterase, or severe ischemic heart disease.

No cases of bambuterol overdose have been reported in humans. However, excessive dosing may lead to elevated terbutaline levels, producing symptoms such as headache, anxiety, tremor, nausea, muscle cramps, palpitations, tachycardia, and cardiac arrhythmias. A drop in blood pressure may also occur. Laboratory findings may include hyperglycemia and lactic acidosis. High doses of β2-agonists can cause hypokalemia due to potassium redistribution.

Short-acting selective β2-adrenoceptor stimulants.

Store below 30°C, protected from light and moisture. Keep out of reach of children.